- (PLX AI) - Genmab Net sales of DARZALEX in the second quarter of 2021 totaled USD 1,433 million.
- • Net trade sales were USD 770 million in the U.S. and USD 663 million in the rest of the world
- • Genmab receives royalties on the worldwide net sales of DARZALEX, both the intravenous and SC formulations, under the exclusive worldwide license to Janssen Biotech